Serum lipid levels and International Prostate Symptom Score or Quality of Life Score are not linked in prostatic hyperplasia.

According to recent research from Turkey, “The relationship between serum lipid levels and measures of benign prostatic hyperplasia was investigated. The study was community based. All the participants had undergone a urological investigation which included International Prostate Symptom Score (I-PSS) and Quality of Life Score (QoL), serum lipid concentrations and determination of prostate volume with transrectal ultrasonography.”

“Body mass index was calculated with the formula of weight (kg)/surface area (m(2)) respectively. Men were considered obese if their body mass index was over 25 kg/m(2). BPH was defined by prostate volume greater than 20 ml and I-PSS greater than seven. Comparisons of serum lipid levels between men with BPH and without BPH were done,” wrote M. Lekili and associates at Celal Bayar University.

Investigators found “no correlation for serum lipid levels with either mean I-PSS and QoL scores. However, triglyceride and cholesterol levels were the lowest in severe symptomatic men than men with low symptoms. Using clinical definition of BPH that prostate volume was greater than 20 ml and I-PSS was greater than seven, men with BPH had not significantly different serum lipid levels from men without BPH.”

The researchers concluded, “Our population-based data reflect that there was no relationship between serum lipid levels and certain physiological measures of lower urinary tract symptoms and clinical benign prostatic hyperplasia.”

Lekili and colleagues published their study in World Journal of Urology (Serum lipid levels in benign prostatic hyperplasia. World J Urol, 2006;24(2):210-213).

For additional information, contact M. Lekili, Celal Bayar University, Faculty Medical, Dept. of Urology, TR-45010 Manisa, Turkey.

Publisher contact information for the World Journal of Urology is: Springer, 233 Spring Street, New York, NY 10013, USA.